Ocrevus is a second-generation humanized anti-CD20 monoclonal antibody for the treatment of primary progressive and relapsing-remitting multiple sclerosis. Ocrevus selectively binds to the CD20 surface antigen on B cells and depletes them from the circulation. Ocrevus is administered by intravenous (IV) infusion.
If you have a Hayes login, click here to view the full report on the Knowledge Center.